Chief Discovery Officer Anatol Kreitzer sold 36,284 shares at $37.09 for $1.3M, cutting 17.2% of his directly held shares with the stock sitting 47.2% above its 90-day low of $25.21 and 8.2% below the 90-day high of $40.43. This mirrors his April 27 sale of $1.3M exactly — two large, near-identical trims in under three months from a senior science officer who has never bought the stock on record — a pattern of consistent reduction that stands out even against a STRONG BUY consensus from 17 of 18 analysts. Bull case: stock holds above $37 into the September 1 earnings print and a beat on the -$1.34 EPS consensus drives a retest of $40.43; bear case: a break below $33 would confirm distribution and open a path back toward the $27 range.

Where it could go — Our conviction 5-6 officer sell signals: 51% beat SPY at 30d; bull holds $37, bear breaks $33.

Jonathan Gillis, CAO and Interim CFO of MPLT, sold 36,979 shares at $37.12 for $1.4M, cutting 20.4% of his directly held shares — with the stock sitting 47% above its 90-day low and 8% below its 90-day high. This is his second major sale in under three months, following a $2.1M sale on April 28, totaling roughly $3.5M in combined proceeds from the same officer while the company carries a consensus EPS estimate of -$1.34 for the next quarter — a pattern of insider distribution that is hard to dismiss as routine diversification. Bull case: stock holds above $37 into the September 1 earnings print and analyst consensus drives a re-rating toward the 90-day high of $40.43; bear case: a break below $27.21 (30-day low) would confirm the distribution pattern is prescient.

Where it could go — Our conviction 5-6 officer sell signals: 51% beat SPY at 30d; bull holds $37, bear breaks $27.21.

Chief Scientific Officer Lillie James Woodruff sold $674K worth of MPLT shares, reducing her direct holdings by 7.5% at a price 46% above the 90-day low. This represents her fourth consecutive sell transaction with no supporting buyers, suggesting routine diversification rather than strong bearish conviction.

Where it could go — Our 5-6 conviction officer sells: 51% beat SPY at 30d with +3.5% average outperformance; watch $40.43 as resistance, $25.21 as support.

CEO Christopher Kroeger sold 147,639 shares at $36.87 for $5.4M, reducing his directly held shares by 10.6% from 1,394,094 to 1,246,455, with the transaction priced 46.1% above the 90-day low and 8.9% below the 90-day high. This is his fifth consecutive sale since April 2026, bringing cumulative proceeds to roughly $12.0M — a sustained, accelerating pattern of distribution that stands in stark contrast to 18 analysts rating the stock a STRONG BUY and zero insider buying across the same period. Bull case: stock holds above $36 into the September 1 earnings catalyst with consensus EPS of -$1.34 already priced in, leaving room for a beat-driven move toward the $40.43 90-day high; bear case: continued CEO selling pressure breaks $27.21 support, the 30-day low.

Where it could go — Our 7-8 conviction officer sell signals: 36% beat SPY at 30d (n=132, avg -7.2% vs SPY); bear breaks $27.21.

CMO Erin Pennock sold 47,158 shares at $36.78 for $1.7M, reducing directly held shares by 13.6% (from 346,059 to 298,901), with the stock sitting 8.9% below its 90-day high of $40.43 and 46% above its 90-day low of $25.21. This is her fourth sale since April, bringing cumulative proceeds to roughly $3.3M — a sustained distribution pattern from a C-suite medical officer that stands out even against a backdrop of 17 buy-rated analyst opinions and no insider buying cluster to offset the signal. Bull case: stock holds above $36 with earnings catalyst on September 1 driving a beat on the consensus EPS of -$1.34; Bear case: continued insider distribution breaks the $27 support level established in May.

Where it could go — Our 5-6 conviction officer sells: 51% beat SPY at 30d (avg +3.5% vs SPY, n=1418); bull holds $36, bear breaks $27.

General Counsel Hanson Kristopher sold $608K worth of MPLT shares at $36.82, reducing his direct holdings by 10.2% in his fourth consecutive sale. While this pattern suggests ongoing distribution, the absence of other insider sellers and strong analyst buy consensus limits the bearish significance of this isolated trade.

Where it could go — Our 5-6 conviction officer sells: 51% beat SPY at 30d with +3.5% average outperformance; watch $40.43 as resistance, $27.21 as support.

CEO Christopher Kroeger sold $3.2M worth of MPLT shares at $27.19, reducing his stake by 7.8% from a position 66.9% above the 90-day low. This first-ever open-market sale from an executive with nine prior sales is a significant directional signal, suggesting the CEO may see limited near-term upside despite the stock's recent rally. Bear: breaks $25.21 (30-day low) → could test $16.30 (90-day low).

Where it could go — No prior pattern data for MPLT; broad base rate for similar signals unavailable. Bear breaks $25.21.

Foff Erin Pennock, Chief Medical Officer, executed an open-market sale (Code S) of 9,180 shares at $27.50 on 2026-05-04, reducing holdings by 2.3% ($252K notional value). This is Pennock's first Form 4 filing on record—no prior buys or sells—making the inaugural action a sale rather than accumulation, which historically underperforms insider buy signals. The stock trades 77.6% above its 90-day low ($15.48) and 17.4% below its 90-day high ($33.28), while 13 analysts maintain STRONG BUY consensus (12 buy, 1 hold); earnings arrive 2026-06-02 with consensus EPS of −$1.12.

Where it could go — If this first-time CMO sale reflects pre-earnings caution or valuation concern, the stock's proximity to 90d highs ($33.28) and STRONG BUY consensus create a bear-case setup requiring confirmation: invalidated if stock holds above $27.50 and rallies into earnings; confirmed if it breaks below the $21.22 30-day low before 2026-06-02.

Foff Erin Pennock, Chief Medical Officer, executed an open-market sale (Code S) of 9,180 shares at $27.50 on 2026-05-04, reducing holdings by 2.3% ($252K notional value). This is Pennock's first Form 4 filing on record—no prior buys or sells—making the inaugural action a sale rather than accumulation, which historically underperforms insider buy signals. The stock trades 77.6% above its 90-day low ($15.48) and 17.4% below its 90-day high ($33.28), while 13 analysts maintain STRONG BUY consensus (12 buy, 1 hold); earnings arrive 2026-06-02 with consensus EPS of −$1.12.

Where it could go — If this first-time CMO sale reflects pre-earnings caution or valuation concern, the stock's proximity to 90d highs ($33.28) and STRONG BUY consensus create a bear-case setup requiring confirmation: invalidated if stock holds above $27.50 and rallies into earnings; confirmed if it breaks below the $21.22 30-day low before 2026-06-02.

Foff Erin Pennock, Chief Medical Officer, executed an open-market sale (Code S) of 9,180 shares at $27.50 on 2026-05-04, reducing holdings by 2.3% ($252K notional value). This is Pennock's first Form 4 filing on record—no prior buys or sells—making the inaugural action a sale rather than accumulation, which historically underperforms insider buy signals. The stock trades 77.6% above its 90-day low ($15.48) and 17.4% below its 90-day high ($33.28), while 13 analysts maintain STRONG BUY consensus (12 buy, 1 hold); earnings arrive 2026-06-02 with consensus EPS of −$1.12.

Where it could go — If this first-time CMO sale reflects pre-earnings caution or valuation concern, the stock's proximity to 90d highs ($33.28) and STRONG BUY consensus create a bear-case setup requiring confirmation: invalidated if stock holds above $27.50 and rallies into earnings; confirmed if it breaks below the $21.22 30-day low before 2026-06-02.

Foff Erin Pennock, Chief Medical Officer, executed an open-market sale (Code S) of 9,180 shares at $27.50 on 2026-05-04, reducing holdings by 2.3% ($252K notional value). This is Pennock's first Form 4 filing on record—no prior buys or sells—making the inaugural action a sale rather than accumulation, which historically underperforms insider buy signals. The stock trades 77.6% above its 90-day low ($15.48) and 17.4% below its 90-day high ($33.28), while 13 analysts maintain STRONG BUY consensus (12 buy, 1 hold); earnings arrive 2026-06-02 with consensus EPS of −$1.12.

Where it could go — If this first-time CMO sale reflects pre-earnings caution or valuation concern, the stock's proximity to 90d highs ($33.28) and STRONG BUY consensus create a bear-case setup requiring confirmation: invalidated if stock holds above $27.50 and rallies into earnings; confirmed if it breaks below the $21.22 30-day low before 2026-06-02.

Chief Medical Officer Erin Pennock executed a Code-S open-market sale of 4,321 shares at $28.52 on 2026-05-07, reducing holdings by 1.2% ($123K notional value). This is Pennock's first Form 4 filing on record—no prior Code-P buys or Code-S sales exist, eliminating any insider trading pattern baseline for this officer. The sale occurred 77.5% above the 90-day low ($16.04) and 14.5% below the 90-day high ($33.28), with zero concurrent Code-P buys from other officers in the past 60 days, indicating no opportunistic cluster accumulation.

Where it could go — Analyst consensus is STRONG BUY (12/13 buy, mean target data unavailable); if thesis holds, the absence of insider buying during a 77.5% rebound from 90d low and first-time seller status suggests liquidity or rebalancing rather than conviction reversal—invalidated if stock breaks below $22.19 (30d low) ahead of 2026-06-02 earnings.

Christopher Kroeger, MPLT CEO and director, executed a Code-S open-market sale of 14,880 shares at $28.47 on 2026-05-07, reducing his holdings from 1,580,820 to 1,565,940 shares (-0.9% stake delta, $424K value). This is Kroeger's first Form 4 filing on record—no prior Code-P buys or Code-S sales—and occurs in isolation with zero other insider buyers in the 60-day cluster window. The sale timing sits 14.5% below the 90-day high ($33.28) and 77.5% above the 90-day low ($16.04), 26 days before earnings (consensus EPS: -$1.12) and despite 12-of-13 analyst STRONG BUY ratings.

Where it could go — If this first-time CEO sale signals confidence loss ahead of negative earnings, the stock historically breaks lower; bear case invalidated if MPLT holds above the $22.19 30-day low and analyst consensus upgrades post-earnings, or if Kroeger re-buys within 90 days.

Christopher Kroeger, MPLT CEO and director, executed a Code-S open-market sale of 14,880 shares at $28.47 on 2026-05-07, reducing his holdings from 1,580,820 to 1,565,940 shares (-0.9% stake delta, $424K value). This is Kroeger's first Form 4 filing on record—no prior Code-P buys or Code-S sales—and occurs in isolation with zero other insider buyers in the 60-day cluster window. The sale timing sits 14.5% below the 90-day high ($33.28) and 77.5% above the 90-day low ($16.04), 26 days before earnings (consensus EPS: -$1.12) and despite 12-of-13 analyst STRONG BUY ratings.

Where it could go — If this first-time CEO sale signals confidence loss ahead of negative earnings, the stock historically breaks lower; bear case invalidated if MPLT holds above the $22.19 30-day low and analyst consensus upgrades post-earnings, or if Kroeger re-buys within 90 days.

Christopher Kroeger, MPLT CEO and director, executed a Code-S open-market sale of 14,880 shares at $28.47 on 2026-05-07, reducing his holdings from 1,580,820 to 1,565,940 shares (-0.9% stake delta, $424K value). This is Kroeger's first Form 4 filing on record—no prior Code-P buys or Code-S sales—and occurs in isolation with zero other insider buyers in the 60-day cluster window. The sale timing sits 14.5% below the 90-day high ($33.28) and 77.5% above the 90-day low ($16.04), 26 days before earnings (consensus EPS: -$1.12) and despite 12-of-13 analyst STRONG BUY ratings.

Where it could go — If this first-time CEO sale signals confidence loss ahead of negative earnings, the stock historically breaks lower; bear case invalidated if MPLT holds above the $22.19 30-day low and analyst consensus upgrades post-earnings, or if Kroeger re-buys within 90 days.

Christopher Kroeger, MPLT CEO and director, executed a Code-S open-market sale of 14,880 shares at $28.47 on 2026-05-07, reducing his holdings from 1,580,820 to 1,565,940 shares (-0.9% stake delta, $424K value). This is Kroeger's first Form 4 filing on record—no prior Code-P buys or Code-S sales—and occurs in isolation with zero other insider buyers in the 60-day cluster window. The sale timing sits 14.5% below the 90-day high ($33.28) and 77.5% above the 90-day low ($16.04), 26 days before earnings (consensus EPS: -$1.12) and despite 12-of-13 analyst STRONG BUY ratings.

Where it could go — If this first-time CEO sale signals confidence loss ahead of negative earnings, the stock historically breaks lower; bear case invalidated if MPLT holds above the $22.19 30-day low and analyst consensus upgrades post-earnings, or if Kroeger re-buys within 90 days.

Christopher Kroeger, MPLT CEO and director, executed a Code-S open-market sale of 14,880 shares at $28.47 on 2026-05-07, reducing his holdings from 1,580,820 to 1,565,940 shares (-0.9% stake delta, $424K value). This is Kroeger's first Form 4 filing on record—no prior Code-P buys or Code-S sales—and occurs in isolation with zero other insider buyers in the 60-day cluster window. The sale timing sits 14.5% below the 90-day high ($33.28) and 77.5% above the 90-day low ($16.04), 26 days before earnings (consensus EPS: -$1.12) and despite 12-of-13 analyst STRONG BUY ratings.

Where it could go — If this first-time CEO sale signals confidence loss ahead of negative earnings, the stock historically breaks lower; bear case invalidated if MPLT holds above the $22.19 30-day low and analyst consensus upgrades post-earnings, or if Kroeger re-buys within 90 days.

General Counsel Kristopher Hanson sold 6,979 shares via Code S (open-market sale) at $30.04 on 2026-05-11, reducing holdings from 175,118 to 168,139 shares (-4.0%), following a $248K sale 7 days prior at $27.50. This represents the second consecutive open-market sale by a first-time Form 4 filer with no prior Code-P buys on record, suggesting sustained liquidation rather than portfolio rebalancing. Stock trades 9.7% below the 90-day high of $33.28 and 84.4% above the 90-day low, with 13-analyst consensus at STRONG BUY; earnings report due 2026-06-02 (22 days) with consensus EPS of -$1.12.

Where it could go — If insider liquidation pattern continues through earnings, historical base rates for consecutive officer Code-S sales by first-time filers show elevated downside risk; bear case invalidated only if stock holds above $24.49 (30d low) and earnings surprise positively on 2026-06-02.

General Counsel Kristopher Hanson sold 6,979 shares via Code S (open-market sale) at $30.04 on 2026-05-11, reducing holdings from 175,118 to 168,139 shares (-4.0%), following a $248K sale 7 days prior at $27.50. This represents the second consecutive open-market sale by a first-time Form 4 filer with no prior Code-P buys on record, suggesting sustained liquidation rather than portfolio rebalancing. Stock trades 9.7% below the 90-day high of $33.28 and 84.4% above the 90-day low, with 13-analyst consensus at STRONG BUY; earnings report due 2026-06-02 (22 days) with consensus EPS of -$1.12.

Where it could go — If insider liquidation pattern continues through earnings, historical base rates for consecutive officer Code-S sales by first-time filers show elevated downside risk; bear case invalidated only if stock holds above $24.49 (30d low) and earnings surprise positively on 2026-06-02.

Kristopher Hanson, General Counsel and officer, executed a Code-S transaction, selling 9,030 shares at $27.50 for $248K, reducing his stake by 4.7% from 190,165 to 181,135 shares. This is a first-time Form 4 filing with no prior Code-P or Code-S history, and no insider cluster activity occurred in the last 60 days. The sale occurred 77.6% above the 90-day low of $15.48, with next earnings due in 29 days and analyst consensus at STRONG BUY despite negative EPS forecast.

Where it could go — In the absence of historical patterns for this insider or ticker, bearish bias stems from timing near the upper range; if thesis holds, mean analyst target implies upside from $27.50, but bear case requires the $15.48 low to hold.